Shopping Cart
Remove All
Your shopping cart is currently empty
Lenzilumab (Synonyms: KB003, KB 003)
Catalog No. T76751 Copy Product Info
🥰Excellent
Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.
Lenzilumab
Copy Product Info🥰Excellent
Catalog No. T76751
Synonyms KB003, KB 003
Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.
Lenzilumab
Cas No. 1229575-09-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $183 | In Stock | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $742 | - | In Stock | |
| 25 mg | $1,120 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.9% (SDS-PAGE); 98.5% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19. |
| In vivo | Intraperitoneal injection of 10 mg/kg Lenzilumab once daily for 10 days improved its antitumor effect in NSG mice by inhibiting GM-CSF without impairing the cellular function of CAR-T and at the same time. [1] |
| Synonyms | KB003, KB 003 |
| Reactivity | Human |
| Verified Activity | Immobilized Human GM-CSF/CSF2 Protein (TMPY-03858) at 1 μg/mL (100 μL/well) can bind Lenzilumab. The EC50 is 10.24 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CSF2/GM-CSF |
| Molecular Weight | 146.81 kDa |
| Cas No. | 1229575-09-0 |
| Isotype | IgG1 |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Lenzilumab | purchase Lenzilumab | Lenzilumab cost | order Lenzilumab | Lenzilumab in vivo | Lenzilumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.